23andMe diabetes test

23andMe adds type 2 diabetes screening to its Health & Ancestry test

The diabetes risk was calculated from the analysis of data 23andMe collected from more than 2.5 million customers who opted in to its research.

FDA greenlights 23andMe’s request to market direct-to-consumer genetic health risk reports

Genetic risk reports for Alzheimer's disease, Parkinson's disease and Hereditary Thrombophilia included in the FDA authorization, among others.

23andMe launches new FDA-cleared service

Called Personal Genome Service, it is touted as an entirely new experience that includes carrier status, wellness, trait and ancestry reports.

23andMe secures $115M Series E round led by Fidelity Management & Research Company

The new funds will help the personal genetics company launch new global user experience, grow its sales efforts and therapeutics discovery group efforts.

23andMe raises $79M to spur its drug development business

Toward the same goal, the company has recently hired Genentech veterans Robert Gentleman and Richard Scheller, who led drug discovery there.

23andMe gets FDA’s approval for Bloom Syndrome test

It's not really the same thing as 23andMe's original offering which screened for 254 diseases, but it's an important step in the right direction.

23andMe launches £125 DNA testing service in the UK

The company's mail-order DNA kits provide customers with an overview of their genetic ancestry, and risk assessments for certain diseases based on genetic data.